Notably, T-cell immunoglobulin mucin-3 (Tim-3) expression levels correlate closely with the Ann-Arbor staging of DLBCL, whereas lymphocyte activation gene 3 (LAG-3) overexpression is strongly associated with poor clinical outcomes (17). Here, LAG3 is linked to diffuse large B-cell lymphoma.